Tuck..... still haven't looked at S-1, but it's number one on "to do" list, maybe just before or after close today. Also haven't had time to review comments of others, if any..........
Xenogen Enters Into a Research Agreement With Pfizer - Program to Study Effects of Genetic Modifications -
ALAMEDA, Calif., Jan. 24 /PRNewswire/ -- Xenogen Corporation announced
that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE)
to develop new methods of identifying potential therapeutic drug targets with
the use of transgenic mice.
"We look forward to working with Pfizer in the area of understanding
genetic modifications and their impact on health and well-being," said Pamela
Reilly Contag, PhD., president and co-CEO of Xenogen Corporation. " We believe
that analyzing gene function is key to choosing targets for drug discovery.
It is our hope that this collaboration with Pfizer will expedite data-mining
processes that may ultimately lead to new drugs and therapies."
The agreement terminates in December 2003, but can be extended at Pfizer's
option for two successive one-year periods.
About Xenogen Corporation
Xenogen Corporation is a leader in the field of real-time in vivo imaging,
providing the pharmaceutical industry with proprietary technologies, products
and services to enable real-time in vivo monitoring to identify drug leads for
clinical development. In addition to pharmaceutical development, Xenogen
believes that its technology has broad applications in other fields, including
biomedical research and toxicology testing in the chemical industry.
Xenogen has recently entered into a series of agreements with leading
pharmaceutical and biotechnology companies. Recent Xenogen milestones include
the granting of a commercial license to a company of Novartis Research
Foundation and the granting of evaluation licenses to Organon, AstraZeneca,
Cell Genesys, Cubist Pharmaceuticals and DuPont Pharmaceuticals.
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including risks cited
in the risk factors sections of Xenogen's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Xenogen disclaims an intent or obligation to update these
forward- looking statements.
For more information, visit the Xenogen web site at xenogen.com
SOURCE Xenogen Corporation
Web Site: xenogen.com hillandknowlton.com |
